201 results on '"Teply, Benjamin A."'
Search Results
2. PAF1-mediated transcriptional reprogramming confers docetaxel resistance in advanced prostate cancer
3. Predictive Value of Multiparametric Magnetic Resonance Imaging in Risk Group Stratification of Prostate Adenocarcinoma
4. Androgen receptor inhibition suppresses anti-tumor neutrophil response against bone metastatic prostate cancer via regulation of TβRI expression
5. Neuropilin-2 axis in regulating secretory phenotype of neuroendocrine-like prostate cancer cells and its implication in therapy resistance
6. A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts
7. Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled Trial.
8. Cardiovascular risks and toxicity - The Achilles heel of androgen deprivation therapy in prostate cancer patients
9. Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer – Clinical Activity and Whole Transcriptome Analysis
10. Prostate Cancer, Version 3.2024
11. Diagnosis of Metastatic Non-Small Cell Lung Cancer during Hospitalization: Missed Opportunity for Optimal Supportive Care?
12. Tumor- and osteoclast-derived NRP2 in prostate cancer bone metastases
13. Current Management of Refractory Germ Cell Tumors
14. Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma: A case report of abscopal toxicities
15. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study
16. Association of plasma NRP2 and VEGF‐C levels with prostate cancer disease severity
17. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
18. Comparison of sequential versus concurrent chemoradiation regimens in non-metastatic muscle-invasive bladder cancer
19. Phase 2 study of olaparib (without ADT) in men with biochemically recurrent prostate cancer (BCR) after prostatectomy.
20. Chapter Five - Deciphering the genetic and epigenetic architecture of prostate cancer
21. Association of plasma NRP2 and VEGF‐C levels with prostate cancer disease severity.
22. Extended follow-up report of a randomized phase II trial comparing gemcitabine and cisplatin with or without berzosertib in patients with advanced urothelial carcinoma.
23. Abstract 2168: Identifying a surrogate biomarker for neuropilin-2 axis in serum of prostate cancer patients
24. A case of metastatic adenoid cystic (basal cell) carcinoma of the prostate: Systemic therapy for a rare disease
25. Early results from a phase 1, multicenter trial of PSCA-specific GoCAR T cells (BPX-601) in patients with metastatic castration-resistant prostate cancer (mCRPC).
26. Androgen-mediated TGFβ expression suppresses anti-tumor neutrophil response in bone metastatic prostate cancer
27. The evolving landscape of PARP inhibitors in castration-resistant prostate cancer: a spotlight on treatment combinations
28. Abstract LB035: Understanding the mechanism of neuropilin2 upregulation in advanced prostate cancer
29. Early discontinuation of abiraterone acetate/prednisone (AA/P) in localized prostate cancer.
30. Precise Engineering of Targeted Nanoparticles by Using Self-Assembled Biointegrated Block Copolymers
31. Targeted Nanoparticle-Aptamer Bioconjugates for Cancer Chemotherapy in vivo
32. Navigating an Optimal Treatment Course for Advanced Kidney Cancer
33. Impact of Performance Status on Response and Survival Among Patients Receiving Checkpoint Inhibitors for Advanced Solid Tumors
34. Biomarkers for Treatment Response in Advanced Prostate Cancer
35. Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma
36. Novel treatment strategy for refractory hemorrhagic cystitis following radiation treatment of genitourinary cancer: Use of 980-nm diode laser
37. The use of charge-coupled polymeric microparticles and micromagnets for modulating the bioavailability of orally delivered macromolecules
38. sj-pdf-1-aop-10.1177_10600280211033938 – Supplemental material for Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients
39. Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)
40. Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients
41. Abstract 1409: Inhibiting Neuropilin-2 overcomes resistance to enzalutamide in prostate cancer
42. Abstract 1422: Neuropilin-2, a potential target against neuroendocrine like therapy resistant prostate cancer
43. Nanoparticle-aptamer bioconjugates for targeted antineoplastic drug delivery
44. Magnetically Responsive Polymeric Microparticles for Oral Delivery of Protein Drugs
45. Formulation of functionalized PLGA–PEG nanoparticles for in vivo targeted drug delivery
46. A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.
47. Can patients with advanced malignancy and poor performance status benefit from nivolumab plus ipilimumab as a palliative treatment?
48. Microfluidic system for studying the interaction of nanoparticles and microparticles with cells
49. NCCN Guidelines Insights: Prostate Cancer, Version 1.2021
50. Anticipating the Next Challenging Clinical Dilemmas in Prostate Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.